Patents by Inventor Gang G. Xu

Gang G. Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11766455
    Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: September 26, 2023
    Assignees: EZY Biotech LLC, Adaerata, Limited Patnership
    Inventors: Hua Gu, Gang G Xu, Adeline Gadzinski, Haijun Tong
  • Publication number: 20200390810
    Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 17, 2020
    Inventors: HUA GU, Gang G Xu, Adeline Gadzinski, Haijun Tong
  • Publication number: 20190298908
    Abstract: This invention is directed to a process for depleting one or more targeted substances such as toxins, proteins such as one or more immune checkpoint inhibitors (ICI), or a combination thereof from a subject. Immune checkpoint inhibitors (ICI), such as PD-1 protein, PD-1 ligand (PD-L1), CTLA-4, LAG-3, TIM3 and others are known to be involved in inhibition of T-cell activation in tumor patients. This invention is also directed to a device for depleting ICI such as PD-1 protein, PD-1 ligand (PD-L1) including soluble PD-L1 (sPD-L1), PD-L2, CTLA-4 including soluble form sCTLA-4, LAG-3, TIM3, or toxins from a subject. This invention is further directed to the use of the process and the devices for treating medical conditions such as cancers, other diseases and substance overdose.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 3, 2019
    Inventors: Yan Chen, Gang G. Xu, Juanjuan Jiang, Juan Sheng